Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +1.20% | +8.55% | -22.21% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.21% | 45.31M | |
+39.73% | 54.04B | |
+43.57% | 41.96B | |
-1.18% | 41.92B | |
-7.59% | 28.35B | |
+12.72% | 26.35B | |
-22.10% | 19B | |
+7.79% | 13B | |
+28.13% | 12.28B | |
+24.68% | 12.19B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- B. Riley Lowers Gain Therapeutics' Price Target to $11 from $16 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions; Keeps Buy Rating